EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Are New β-Lactam/β-Lactamase Inhibitor Combinations Promising Against Carbapenem-Resistant K. pneumoniae Isolates?

Ayşe Nur Ceylan iD, Selda Kömeç iD, Kamuran Şanlı iD, Beyza Öncel, Mehmet Akif Durmuş iD, Abdurrahman Gülmez iD

Pathogens · 2025

DOI: 10.3390/pathogens14030220 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathogens, 2025. Verfasst von Ayşe Nur Ceylan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Microbiology, Basaksehir Çam and Sakura City Hospital, University of Health Science, Istanbul 34480, Türkiye. Hauptthemen laut MEDLINE: Klebsiella pneumoniae, beta-Lactamase Inhibitors, Anti-Bacterial Agents, Klebsiella Infections. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Carbapenem-resistant Klebsiella pneumoniae (CRKP) infections present a significant clinical challenge due to limited therapeutic options and high transmission potential. This study aimed to identify the resistance genes associated with carbapenemase production in CRKP isolates and evaluate the in vitro activity of ceftazidime/avibactam (CZA) and meropenem/vaborbactam (MEV), among other β-lactam/β-lactamase inhibitor combinations.

Methods

Between October 2021 and June 2022, a total of 504 CRKP isolates were grown from patient samples in intensive care units. When duplicate patient samples were removed, the remaining 89 isolates were included in the study. Bacterial identification and antimicrobial susceptibility testing were per-formed using MALDI-TOF, Phoenix M50, and disk diffusion methods, following EUCAST guidelines. PCR analyses identified carbapenemase genes such as OXA-48, NDM, and KPC.

Results

The most prevalent carbapenemase gene was OXA-48 (79.8%), followed by NDM (21.4%) and KPC (17.9%). The susceptibility rate to CZA was 82.0%, significantly higher than MEV (10.1%). All isolates were resistant to piperacillin/tazobactam and ceftolozane/tazobactam. Among MEV-resistant isolates, most carried the OXA-48 gene, while NDM was common in CZA-resistant isolates.

Conclusions

CZA demonstrates high efficacy against OXA-48-producing CRKP, making it a viable treatment option in settings where OXA-48 predominates. The limited activity of MEV in this study underscores the need for molecular surveillance of resistance mechanisms to guide empirical therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Klebsiella pneumoniaebeta-Lactamase InhibitorsAnti-Bacterial AgentsKlebsiella InfectionsCarbapenem-Resistant EnterobacteriaceaeHumansMicrobial Sensitivity TestsAzabicyclo CompoundsDrug Combinationsbeta-LactamasesBacterial ProteinsCeftazidimeCarbapenemsMeropenembeta-LactamsBoronic AcidsHeterocyclic Compounds, 1-Ring

Stichwörter der Autor:innen

KPCNDMOXA-48carbapenem-resistant Klebsiella pneumoniaeceftazidime/avibactammeropenem/vaborbactam

Substanzen

beta-Lactamase InhibitorsAnti-Bacterial AgentsAzabicyclo CompoundsDrug Combinationsbeta-LactamasesBacterial ProteinsCeftazidimeavibactam, ceftazidime drug combinationCarbapenemscarbapenemase

Autor:innen und Institutionen

  • Department of Medical Microbiology, Basaksehir Çam and Sakura City Hospital, University of Health Science, Istanbul 34480, Türkiye.
  • Medical Microbiology Laboratory, Aydın Ataturk State Hospital, Aydın 09020, Türkiye.

ORCID-Profile: Ayşe Nur Ceylan, Selda Kömeç, Kamuran Şanlı, Mehmet Akif Durmuş, Abdurrahman Gülmez

Zitieren

APA

Ceylan, A. N., Kömeç, S., Şanlı, K., Öncel, B., Durmuş, M. A., & Gülmez, A. (2025). Are New β-Lactam/β-Lactamase Inhibitor Combinations Promising Against Carbapenem-Resistant K. pneumoniae Isolates?. Pathogens. https://doi.org/10.3390/pathogens14030220

Vancouver

Ceylan AN, Kömeç S, Şanlı K, Öncel B, Durmuş MA, Gülmez A. Are New β-Lactam/β-Lactamase Inhibitor Combinations Promising Against Carbapenem-Resistant K. pneumoniae Isolates?. Pathogens. 2025. doi:10.3390/pathogens14030220

BibTeX
@article{Ceylan2025,
  author = {Ceylan, Ayşe Nur and Kömeç, Selda and Şanlı, Kamuran and Öncel, Beyza and Durmuş, Mehmet Akif and Gülmez, Abdurrahman},
  title = {Are New β-Lactam/β-Lactamase Inhibitor Combinations Promising Against Carbapenem-Resistant K. pneumoniae Isolates?},
  journal = {Pathogens},
  year = {2025},
  doi = {10.3390/pathogens14030220}
}
Kostenlos starten →